MORPHIC HOLDING INC (MORF)
US61775R1059 - Common Stock
MORF gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. While MORF has a great health rating, there are worries on its profitability. MORF has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year MORF has reported negative net income.
In the past year MORF has reported a negative cash flow from operations.
In the past 5 years MORF always reported negative net income.
In the past 5 years MORF always reported negative operating cash flow.
1.2 Ratios
With a decent Return On Assets value of -27.83%, MORF is doing good in the industry, outperforming 71.70% of the companies in the same industry.
The Return On Equity of MORF (-29.08%) is better than 81.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.83% | ||
| ROE | -29.08% | ||
| ROIC | N/A |
ROA(3y)-19.83%
ROA(5y)-19.11%
ROE(3y)-22.37%
ROE(5y)-25.77%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for MORF so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
MORF does not have a ROIC to compare to the WACC, probably because it is not profitable.
MORF has more shares outstanding than it did 1 year ago.
MORF has more shares outstanding than it did 5 years ago.
There is no outstanding debt for MORF. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 60.78 indicates that MORF is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 60.78, MORF belongs to the best of the industry, outperforming 98.42% of the companies in the same industry.
There is no outstanding debt for MORF. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 60.78 |
ROIC/WACCN/A
WACC10.56%
2.3 Liquidity
A Current Ratio of 24.13 indicates that MORF has no problem at all paying its short term obligations.
MORF has a better Current ratio (24.13) than 95.43% of its industry peers.
A Quick Ratio of 24.13 indicates that MORF has no problem at all paying its short term obligations.
MORF has a Quick ratio of 24.13. This is amongst the best in the industry. MORF outperforms 95.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 24.13 | ||
| Quick Ratio | 24.13 |
3. Growth
3.1 Past
MORF shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -15.74%.
Looking at the last year, MORF shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
MORF shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -31.12% yearly.
EPS 1Y (TTM)-15.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-77.37%
Revenue growth 5Y-31.12%
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, MORF will show a small growth in Earnings Per Share. The EPS will grow by 0.11% on average per year.
The Revenue is expected to grow by 213.82% on average over the next years. This is a very strong growth
EPS Next Y-16.05%
EPS Next 2Y-11.1%
EPS Next 3Y-8.78%
EPS Next 5Y0.11%
Revenue Next Year-50.42%
Revenue Next 2Y-24.72%
Revenue Next 3Y-7.43%
Revenue Next 5Y213.82%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
MORF reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MORF is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as MORF's earnings are expected to decrease with -8.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.1%
EPS Next 3Y-8.78%
5. Dividend
5.1 Amount
No dividends for MORF!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MORPHIC HOLDING INC
NASDAQ:MORF (8/15/2024, 8:13:37 PM)
After market: 56.99 0 (0%)56.99
+0.02 (+0.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners1.36%
Inst Owner Change-98.5%
Ins Owners15.53%
Ins Owner Change-64.38%
Market Cap2.85B
Analysts73.33
Price Target59.6 (4.58%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.15%
Min EPS beat(2)-15.97%
Max EPS beat(2)3.68%
EPS beat(4)2
Avg EPS beat(4)0.47%
Min EPS beat(4)-15.97%
Max EPS beat(4)25.02%
EPS beat(8)4
Avg EPS beat(8)3.24%
EPS beat(12)6
Avg EPS beat(12)16.34%
EPS beat(16)7
Avg EPS beat(16)16.75%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.22%
PT rev (3m)0.22%
EPS NQ rev (1m)1.34%
EPS NQ rev (3m)-2.79%
EPS NY rev (1m)0.1%
EPS NY rev (3m)-2.52%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-12.5%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 4.62 | ||
| P/tB | 4.62 | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.75
EYN/A
EPS(NY)-4.33
Fwd EYN/A
FCF(TTM)-2.75
FCFYN/A
OCF(TTM)-2.72
OCFYN/A
SpS0
BVpS12.35
TBVpS12.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.83% | ||
| ROE | -29.08% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-19.83%
ROA(5y)-19.11%
ROE(3y)-22.37%
ROE(5y)-25.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 120.75% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 24.13 | ||
| Quick Ratio | 24.13 | ||
| Altman-Z | 60.78 |
F-Score2
WACC10.56%
ROIC/WACCN/A
Cap/Depr(3y)83.14%
Cap/Depr(5y)112.12%
Cap/Sales(3y)81.29%
Cap/Sales(5y)51.56%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-15.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
EPS Next Y-16.05%
EPS Next 2Y-11.1%
EPS Next 3Y-8.78%
EPS Next 5Y0.11%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-77.37%
Revenue growth 5Y-31.12%
Sales Q2Q%N/A
Revenue Next Year-50.42%
Revenue Next 2Y-24.72%
Revenue Next 3Y-7.43%
Revenue Next 5Y213.82%
EBIT growth 1Y-49.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-29.66%
EBIT Next 3Y-21.14%
EBIT Next 5YN/A
FCF growth 1Y-41.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-41.79%
OCF growth 3YN/A
OCF growth 5YN/A